Verify whether this represents actual policy change or continuation of existing Medicare negotiation authority established under the 2022 Inflation Reduction Act.
This is a continuation of the Biden-era Inflation Reduction Act's Medicare drug negotiation program, not a new Trump policy initiative. The announcement adds drugs to an existing framework with no constitutional implications (A=0). The modest B score (23) reflects credit-claiming for a predecessor's policy during a week crowded with higher-stakes events, fitting the 'credit-grab' noise pattern.